Literature DB >> 27815866

Comment on: "Modeling the Relationship between Exposure to Abiraterone and Prostate-Specific Antigen Dynamics in Patients with Metastatic Castration-Resistant Prostate Cancer".

Nuggehally R Srinivas1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 27815866     DOI： 10.1007/s40262-016-0468-2

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN： 0312-5963            Impact factor:   6.447


× No keyword cloud information.
  2 in total

1.  Modeling the Relationship Between Exposure to Abiraterone and Prostate-Specific Antigen Dynamics in Patients with Metastatic Castration-Resistant Prostate Cancer.

Authors:  Xu Steven Xu; Charles J Ryan; Kim Stuyckens; Matthew R Smith; Fred Saad; Thomas W Griffin; Youn C Park; Margaret K Yu; Peter De Porre; An Vermeulen; Italo Poggesi; Partha Nandy
Journal:  Clin Pharmacokinet       Date:  2017-01       Impact factor: 6.447

2.  Conversion of abiraterone to D4A drives anti-tumour activity in prostate cancer.

Authors:  Zhenfei Li; Andrew C Bishop; Mohammad Alyamani; Jorge A Garcia; Robert Dreicer; Dustin Bunch; Jiayan Liu; Sunil K Upadhyay; Richard J Auchus; Nima Sharifi
Journal:  Nature       Date:  2015-06-01       Impact factor: 49.962
  2 in total
  1 in total

1.  Author's Reply to Srinivas: "Modeling the Relationship Between Exposure to Abiraterone and Prostate-Specific Antigen Dynamics in Patients with Metastatic Castration-Resistant Prostate Cancer".

Authors:  Steven Xu; Peter De Porre
Journal:  Clin Pharmacokinet       Date:  2017-02       Impact factor: 6.447
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.